Besides, the combination of anti-PD-L1/PD-1 blockade with chemoradiotherapy has also shown promising results, especially in NSCLC patients, who have achieved higher overall efficacy and survival rate in the combined treatment 63. Here, PDCD1 is linked to non-small cell lung carcinoma.